Subgroup
ABI*
Median (mo)
Placebo*
Median (mo)
Favors
ABI+P
Favors
Placebo+P
HR (95% CI)
Baseline ECOG PS*: 0-1
Baseline ECOG PS*: 2
17.0
7.3
12.3
7.0
0.74 (0.63-0.86)
0.77 (0.50-1.17)
Baseline BPI-SF score <4
Baseline BPI-SF score ≥4
18.4
13.3
13.9
9.3
0.69 (0.59-0.85)
0.78 (0.63-0.96)
Number of CT regimens: 1
Number of CT regimens: 2
17.1
14.2
11.7
10.4
0.71 (0.59-0.85)
0.80 (0.61-1.03)
Type of progression: PSA only
Type of progression: Radiographic
18.3
14.8
13.6
10.5
0.63 (0.47-0.84)
0.78 (0.65-0.93)
Age <65 years
Age ≥65 years
Age ≥75 years
15.0
16.2
15.6
11.2
11.1
9.3
0.69 (0.53-0.91)
0.76 (0.63-0.90)
0.64 (0.48-0.85)
Visceral disease at entry: yes
Visceral disease at entry: no
12.9
17.1
8.3
12.3
0.79 (0.59-1.05)
0.69 (0.58-0.82)
Baseline PSA >median: yes
Baseline PSA >median: no
13.6
18.2
8.8
15.3
0.65 (0.53-0.79)
0.79 (0.63-0.99)
Baseline LDH >median: yes
Baseline LDH >median: no
10.4
20.8
8.0
18.0
0.77 (0.63-0.93)
0.75 (0.59-0.96)
Baseline ALK-P >median: yes
Baseline ALK-P >median: no
12.4
19.5
8.1
18.0
0.60 (0.50-0.74)
0.88 (0.69-1.12)
Fizazi K et al. Lancet Oncol 2012;13:983-92
;
COU-AA-301: OS not influenced by age
1
1.25
0.75
0.5
SAEU.CAB.16.07.0040j
